Immunotherapy

Phase 3Small molecule

Bristol-Myers Squibb

Immunotherapy is one of 643 small molecule programs targeting Gastroparesis. It is currently in Phase 3.

Indications

108

Total Trials

Active Trials

642

Competitors

Pipeline

Status by Indication[3][1]

Indication

GastroparesisActive, not recruiting

Gastroesophageal Junction AdenocarcinomaNot yet recruiting

Esophageal Squamous Cell CarcinomaRecruiting

Lung CancerRecruiting

Esophageal CancerRecruiting

Skin CancerActive, not recruiting

Metastatic MelanomaActive, not recruiting

Physical ActivityActive, not recruiting

Uveal MelanomaRecruiting

Breast CarcinomaRecruiting

GastroparesisPreclinical

Active, not recruiting

Gastroesophageal Junction AdenocarcinomaPhase 2

Not yet recruiting

Esophageal Squamous Cell CarcinomaPhase 3

Recruiting

Lung CancerPhase 2

Recruiting

Esophageal CancerPhase 3

Recruiting

Skin CancerPreclinical

Active, not recruiting

Metastatic MelanomaPreclinical

Active, not recruiting

Physical ActivityPreclinical

Active, not recruiting

Uveal MelanomaPhase 2

Recruiting

Breast CarcinomaPhase 1

Recruiting

Showing 10 of 32 indications

Competition

Competitive Landscape

706 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Immunotherapy

Bristol-Myers Squibb

Phase 3

2 2

Adenocard

Astellas

Preclinical

2 3

Cortef

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 4

Duragesic

CCephalon

Preclinical

1 5

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 6

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 7

Rilvegostomig

AstraZeneca

Preclinical

1 8

Vfend

PPrism Pharmaceuticals

Systemic Therapy

1 10

4SCAR T Cells

SShenzhen Geno-Immune Medical Institute

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Neoadjuvant Chemotherapy

NCT05202314

Recruiting

Lung Cancer

NCT06788366

Phase 2Recruiting

Prostate Cancer

NCT06249750

Q2 2027

Phase 2Recruiting

Chemotherapy

NCT05507411

Q4 2027

Phase 1Not yet recruiting

Advanced NSCLC

NCT06966583

PreclinicalRecruiting

Metastatic Lung Non-Small Cell Carcinoma

NCT04151940

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer12 trials

Differences in Rate of Decline in CT-defined Skeletal Muscle Mass and Physical Performance in Patients With Advanced Non-small Cell Lung Cancer Receiving Chemotherapy and Targeted Therapy/Immunotherapy, Before and After Treatment.

Recruiting·PPrince of Songkla University··NCT06326086·240 enrolled

Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy

Unknown status·IInstitut Cancerologie de l'Ouest·Phase 3·NCT05111197·112 enrolled

Combined Statin and PD-1/PD-L1 Inhibitors in Treating Non-small Cell Lung Cancer

Active, not recruiting·TThe Fourth Affiliated Hospital of Zhejiang University School of Medicine··NCT05636592·250 enrolled

Show 9 more trials

Efficacy and Safety of High-Dose Rate Brachytherapy with Immunotherapy and Chemotherapy As Second-Line Treatment for Advanced Non-Small Cell Lung Cancer

Active, not recruiting·TThe First People's Hospital of Neijiang··NCT06518018·80 enrolled

Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer

Recruiting·KKong Fanming·Phase 2/3·NCT07034326·405 enrolled

Evaluating Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy Followed by Consolidation Immunotherapy for Locally Advanced Non-small Cell Lung Cancer

Withdrawn·SSun Yat-sen University·Phase 2·NCT05481775

The Predictive Biomarkers in Patients With Locally Advanced Non-small Cell Lung Cancer

Unknown status·—··NCT06287320·200 enrolled

SRS Timing With Immune Checkpoint Inhibition in Patients With Untreated Brain Metastases From Non-small Cell Lung Cancer

Withdrawn·—·Phase 2·NCT04650490

Efficacy and Safety of Chemoimmunotherapy and Carbon Ion Radiotherapy in Unresectable Locally Advanced Non-small Cell Lung Cancer

Not yet recruiting·JJi Yongling··NCT07035860·34 enrolled

Relation Between Tumor-draining Lymph Nodes Metastasis Pattern and Non-small Cell Lung Cancer Neoadjuvant Immunotherapy Effectiveness

Completed·SSun Yat-sen University··NCT06292052·209 enrolled

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Terminated·WWake Forest University Health Sciences·Phase 2·NCT02949843·19 enrolled

ARGONAUT: Development and Analysis of a Blood and Stool Sample Bank for Cancer Patients, Enabling the Systematic Study of the Effect of Gut Microbiomes on Response to Treatment

Suspended·PPersephone Biosciences··NCT04638751·5,000 enrolled

Immunotherapy10 trials

Nasal Mucus Proteome and Immunotherapy

Recruiting·MMedical University of Graz··NCT02159404·88 enrolled

Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07231575·39 enrolled

CAREMM-2306: Advanced Immunotherapy vs. Classical Immunotherapy

Unknown status·SSeoul St. Mary's Hospital··NCT06202885·2,500 enrolled

Show 7 more trials

Ajuvant Chemotherapy and Immunotherapy in Patients With Esophageal, Esophageal- Gastric Junction Cancer

Recruiting·TThe Second Hospital of Shandong University·N/A·NCT04688801·200 enrolled

A Study to Evaluate Satisfaction With Care in Patients With Cancer Receiving Immunotherapy Treatment at Home

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb··NCT06163053·49 enrolled

Sublingual Immunotherapy Studies for Grass and Dust Mite Allergies

Completed·SStanford University·Phase 1·NCT01529437·31 enrolled

Immunotherapy and Carbon Ion Radiotherapy In Solid Cancers With Stable Disease

Recruiting·CCNAO National Center of Oncological Hadrontherapy·Phase 2·NCT05229614·27 enrolled

Tolerance Results and Immune Mechanisms in Cow´s Milk and/or Hen´s Egg Allergic Children Following Natural Evolution or Oral Immunotherapy

Recruiting·FFundación de Investigación Biomédica - Hospital Universitario de La Princesa·Phase 1/2·NCT07419243·68 enrolled

Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients

Completed·AALK-Abelló A/S·Phase 2·NCT00857779·473 enrolled

Effect of Sublingual Immunotherapy on Platlet factor4 Level in Children

Unknown status·ZZagazig University·Phase 3·NCT04851860·30 enrolled

Lung Cancer5 trials

CIETAI and Sequential Radiotherapy in Squamous Lung Cancer

Recruiting·DDong Wang·Phase 2·NCT05892237·50 enrolled

Daily Adaptive Radiation Therapy: An Individualized Approach for Stage III Lung Cancer

Withdrawn·VVarian, a Siemens Healthineers Company·N/A·NCT05488626

AI-HOPE Lung Cancer: Building a Predictive Tool for Metastatic Lung Cancer

Recruiting·IIRCCS San Raffaele··NCT06788366·2,000 enrolled

Show 2 more trials

Association of Psychological Distress in Patients With Lung Cancer

Recruiting·SShanghai Chest Hospital··NCT06218901·500 enrolled

A Multi-Center Pilot Biomarker Study With Cardiopulmonary Monitoring in Lung Cancer Patients Receiving Combined Thoracic Radiotherapy and Immunotherapy

Recruiting·BBo Lu··NCT06410300·125 enrolled

Esophageal Cancer4 trials

Neoadjuvant Treatment Modalities in Esophageal Cancer

Recruiting·—·Phase 3·NCT04821843·2,000 enrolled

A Retrospective Clinical Study Exploring Prognostic Factors in Esophageal Cancer Patients

Active, not recruiting·NNanfang Hospital, Southern Medical University··NCT06960889·500 enrolled

Surgery or Definitive Chemoradiotherapy in Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma Achieving Clinical Response After Neoadjuvant Chemoimmunotherapy: A Prospective, Preference-Based, Comparative Two-Cohort Phase II Trial (SORT Trial)

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07162506·120 enrolled

Show 1 more trial

Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma: A Randomized Prospective Clinical Study (OMEC-5)

Recruiting·AAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)·Phase 2·NCT07000253·290 enrolled

Esophageal Squamous Cell Carcinoma3 trials

Immunotherapy Combined With Chemoradiotherapy for First-line Treatment of Esophageal Squamous Cell Carcinoma（ChinECR）

Active, not recruiting·HHebei Medical University Fourth Hospital·N/A·NCT06478355·800 enrolled

Radiotherapy Combined With Immunochemotherapy in Metastatic Esophageal Squamous Cell Carcinoma

Recruiting·SShanghai Chest Hospital·Phase 2·NCT05978193·100 enrolled

Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma

Recruiting·PPeking Union Medical College Hospital·Phase 2/3·NCT06907602·120 enrolled

56 more indications

Immunochemotherapy3 trials

Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC

Recruiting·UUniversity Hospital, Bonn·Phase 2·NCT06810609·176 enrolled

Compare Clinical Outcomes Between Advanced Immunotherapy and Classical Immunochemotherapy in RRMM

Unknown status·SSeoul St. Mary's Hospital··NCT06205823·1,600 enrolled

Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy

Unknown status·ZZhejiang Cancer Hospital·Phase 3·NCT06031597·105 enrolled

Melanoma3 trials

Surgery of Melanoma Metastases After Systemic Therapy

Withdrawn·VVastra Gotaland Region·Phase 2·NCT04242329

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Recruiting·LLinnaeus Therapeutics, Inc.·Phase 2/3·NCT06624644·135 enrolled

Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma Management

Recruiting·UUniversity Hospital, Montpellier··NCT06627595·160 enrolled

Advanced NSCLC2 trials

ctDNA as a Biomarker for Treatment in Advanced NSCLC

Unknown status·FFuzhou General Hospital··NCT05486988·500 enrolled

NAD+ Supplement（NMN）With Radioimmunotherapy in Advanced NSCLC

Not yet recruiting·SSichuan University·Phase 1·NCT06966583·20 enrolled

Chemoradiotherapy2 trials

PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC

Recruiting·TTheraOp·Phase 2·NCT06102057·110 enrolled

Chemoradiotherapy in Esophageal or Esophagogastric Junction Cancer

Recruiting·—·Phase 3·NCT04821778·2,000 enrolled

Neoadjuvant Therapy2 trials

Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC

Recruiting·FFirst People's Hospital of Hangzhou·Phase 2·NCT06718309·40 enrolled

Iparomlimab and Tuvonralimab Combined With Paclitaxel and Cisplatin as Neoadjuvant Therapy for CC

Recruiting·OObstetrics & Gynecology Hospital of Fudan University·Phase 2·NCT06878222·35 enrolled

Breast Cancer2 trials

The Clinical Significance of Cellular Immune Adjuvant Therapy of Triple Negative Breast Cancer

Withdrawn·FFirst Affiliated Hospital Xi'an Jiaotong University·Phase 2·NCT02539017

Combined Chemo-immunotherapy Plus SBRT in Neoadjuvant Treatment for Luminal Subtype Breast Cancer

Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Phase 2·NCT07254858·302 enrolled

Immune Checkpoint Inhibitors2 trials

Hyperthermia Combined With Immune Checkpoint Inhibitors in the Treatment of Advanced Gastrointestinal Malignancies With Liver Metastases

Not yet recruiting·—·Phase 2·NCT07118566·40 enrolled

Analyzing Clinical Outcomes and Genomic Data of American Indian Patient Population Treated With Immune Checkpoint Inhibitors for Various Cancers

Active, not recruiting·UUniversity of Oklahoma··NCT05863052·72 enrolled

Small Cell Lung Cancer2 trials

Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)

Recruiting·FFudan University·Phase 2·NCT06943235·60 enrolled

Concurrent Chemoradiotherapy Combined With Toripalimab and Surufatinib in the Treatment of Limited-Stage Small Cell Lung Cancer

Recruiting·SSun Yat-sen University·Phase 2·NCT06719700·47 enrolled

Allergic Asthma2 trials

e-ITAG Allergen Immunotherapy in the Management of Allergic Asthma

Unknown status·GGeneral Administration of Military Health, Tunisia··NCT06021912·300 enrolled

Study to Evaluate the Effect of Omalizumab on Improving the Tolerability of Specific Immunotherapy in Patients With Persistent Allergic Asthma

Completed· Novartis logo

Novartis·Phase 4·NCT00267202·275 enrolled

Locally Advanced2 trials

HEFTME System for Adjuvant Therapeutic Selection of Locally Advanced UTUC Postoperatively：A Perspective Cohort Study

Not yet recruiting·PPeking University First Hospital··NCT06798246·200 enrolled

TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC

Recruiting·FFudan University·Phase 3·NCT06676449·432 enrolled

Neoadjuvant Chemotherapy2 trials

Radiotherapy With Neoadjuvant Chemotherapy and Immunotherapy in Rectal Cancer

Suspended·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology·Phase 1/2·NCT04558684·30 enrolled

Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer

Recruiting·—·N/A·NCT05202314·20 enrolled

Neoadjuvant Immunotherapy2 trials

Neoadjuvant Immunotherapy in Advanced NSCLC

Unknown status·PPower Life Sciences Inc.··NCT05137912·10 enrolled

The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China

Recruiting·GGuangdong Association of Clinical Trials··NCT04286841·100 enrolled

Medication2 trials

Clinical Utilization of Newly Approved Oncology Medications

Unknown status·NNational Guard Health Affairs··NCT02783885·100 enrolled

Validation of Combined Symptom Medication Score (cSMS) in Allergic Patients

Completed·LLeti Pharma GmbH··NCT03850626·168 enrolled

Colorectal Cancer2 trials

Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT06356584·62 enrolled

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal Cancer: Phase II Study

Not yet recruiting·WWest China Hospital·Phase 2·NCT07904130·32 enrolled

Camrelizumab1 trial

Camrelizumab Combined With Local Treatment in NSCLC Patients With BM

Unknown status·ZZhejiang Cancer Hospital·Phase 2·NCT04291092·63 enrolled

Gastroesophageal Junction Adenocarcinoma1 trial

Factors Influencing Immunotherapy Response in dMMR/MSI-H Gastric/Gastroesophageal Junction Adenocarcinoma

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT07259473·15 enrolled

Head and Neck Cancers1 trial

Changes in the Microenvironment of HPV-induced Head and Neck Cancers in West Indies and Metropolitan Population

Completed·UUniversity Hospital Center of Martinique··NCT03580070·140 enrolled

Safety and Efficacy1 trial

Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases

Not yet recruiting·SSichuan University·Phase 2·NCT07258147·30 enrolled

Organoid1 trial

Organoid Model Predictive of Response to Immunotherapies

Terminated·IIndiana University··NCT06084676·1 enrolled

Uveal Melanoma1 trial

A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma

Recruiting·—·Phase 2·NCT05077280·40 enrolled

Rectal Cancer1 trial

SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer

Not yet recruiting·SSun Yat-sen University·Phase 2·NCT07297030·37 enrolled

Adjuvant Chemotherapy1 trial

Adjuvant Radioimmunotherapy Compared With Adjuvant Chemotherapy for UTUC

Recruiting·PPeking University First Hospital··NCT06120374·178 enrolled

Effects of Immunotherapy1 trial

Gender Difference in sidE eFfects of ImmuNotherapy: a Possible Clue to Optimize cancEr tReatment

Completed·FFondazione IRCCS Istituto Nazionale dei Tumori, Milano··NCT04435964·247 enrolled

Crohn's Disease1 trial

Prospective Cohort Establishment and Clinical Observation of Children With Crohn's Disease

Active, not recruiting·TTongji Hospital··NCT06673134·100 enrolled

Immune Checkpoint Inhibitor1 trial

Immune Checkpoint Inhibitor Therapy- Induced Endocrinopathy

Unknown status·NNational Taiwan University Hospital··NCT04079647·200 enrolled

NSCLC1 trial

The Effects of an Nutritional Intervention on PD-1 ICI in NSCLC

Completed·—·N/A·NCT05902260·51 enrolled

Hematologic Malignancies1 trial

Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies

Completed·SSt. Jude Children's Research Hospital·Phase 1·NCT00697671·48 enrolled

Non-Small Cell Lung Carcinoma1 trial

Survival Efficacy of Combined Radiotherapy and Immunotherapy in Patients With Metastatic Non-small Cell Lung Carcinoma

Completed·HHopitaux Prives de Metz, Groupe UNEOS··NCT07111104·350 enrolled

Bladder Cancer1 trial

Evaluating the Impact of 18F-FDG-PET-CT on Risk Stratification and Treatment Adaptation for Patients with Muscle Invasive Bladder Cancer

Recruiting·UUniversity Hospital, Ghent·Phase 2·NCT04724928·156 enrolled

Metastatic Melanoma1 trial

Efficacy of First-Line Immunotherapy in Metastatic Melanoma in Slovenia and Identification of Predictive Biomarkers

Recruiting·IInstitute of Oncology Ljubljana·N/A·NCT07407166·40 enrolled

Chemotherapy1 trial

Watch and Wait for NeoAdjuvant Concurrent Radiochemotherapy Combined With Camrelizumab in Patients With Resectable ESCC

Recruiting·ZZhejiang Cancer Hospital·Phase 2·NCT05507411·100 enrolled

Gastroparesis1 trial

Gastroparesis Outcome Longitudinal Database Enrolled Numerically

Recruiting·UUniversity of Louisville··NCT03876288·3,000 enrolled

Pathological Complete Response1 trial

The Efficacy and Safety of Adjuvant Immunotherapy After Pathological Complete Response Following Neoadjuvant Chemoimmunotherapy in Patients with Resectable NSCLC

Active, not recruiting·XXiangya Hospital of Central South University··NCT06243679·100 enrolled

Head and Neck Squamous Cell Carcinoma1 trial

Identification of Predictive Factors for the Response to Anti-Programmed Cell Death Protein 1 (PD1) Immunotherapy in Head and Neck Squamous Cell Carcinoma

Recruiting·IInstitut de cancérologie Strasbourg Europe··NCT05328024·60 enrolled

Prostate Cancer1 trial

Clinical Application of Near-infrared Whole Body Heat Shock Multimodal Technique in Treatment of Castration-resistant Prostate Cancer

Recruiting·PPengyuan Liu·Phase 2·NCT06249750·60 enrolled

Skin Cancer1 trial

How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes

Terminated·WWashington University School of Medicine··NCT03370861·54 enrolled

ESS1 trial

QUantitative Assessment of Swallowing After Radiation (QUASAR)

Unknown status·—··NCT04359199·42 enrolled

Hypofractionated Radiotherapy1 trial

Neoadjuvant Moderately Hypofractionated Radiotherapy Combined with Chemotherapy and Immunotherapy for High-risk LARC

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT06599827·54 enrolled

Treatment Duration1 trial

Observational Retro-prospective Study on PD1/PDL1 Inhibitors Treatment Duration in Patients With NSCLC

Unknown status·UUniversity of Milano Bicocca··NCT05418660·300 enrolled

Metastatic Colorectal Cancer1 trial

Retrospective Study on the Use of Immunotherapy in Patients With MSI-H Metastatic Colorectal Cancer

Active, not recruiting·GGruppo Oncologico Italiano di Ricerca Clinica··NCT04612309·100 enrolled

Oligometastases1 trial

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.

Recruiting·DDavid Palma·Phase 3·NCT05717166·180 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Trial of SLITone(TM) Birch in Subjects With Hayfever

Completed·AALK-Abelló A/S·Phase 3·NCT00310466·226 enrolled

Rhinitis1 trial

Sublingual Immunotherapy In Alternaria-Induced Rhinitis

Completed·UUniversity of Genova·Phase 4·NCT01127035·27 enrolled

Allergic Rhinitis1 trial

Effect and Underlying Immunological Mechanisms of Sublingual Immunotherapy in Allergic Rhinitis

Completed·—·Phase 3·NCT03649139·71 enrolled

Atopic Dermatitis1 trial

Efficacy and Safety Trial of ALK-depot SQ Mites in Subjects With Atopic Dermatitis

Completed·AALK-Abelló A/S·Phase 3·NCT00310492·154 enrolled

Efficacy1 trial

Efficacy and Tolerability of Two Different Administration Routes With SLITonePLUS Birch

Completed·AALK-Abelló A/S·Phase 2·NCT01191359·66 enrolled

Asthma1 trial

Effect of Specific Immunotherapy to Dust Mites in Children With Asthma

Unknown status·MMedical University of Lodz·Phase 4·NCT00496561·80 enrolled

Breast Carcinoma1 trial

A Phase I Study of M5A-IL2 Immunocytokine Combined With Stereotactic Body Radiation Therapy (SBRT) in Patients With Metastatic Colorectal Cancer or CEA-Positive Metastatic Breast Cancer

Recruiting·CCity of Hope Medical Center·Phase 1·NCT06130826·24 enrolled

Hepatocellular Carcinoma1 trial

Bevacizumab Plus Iparomlimab/Tuvonralimab With Hepatic Artery Infusion Chemotherapy Followed by Surgical Resection or Stereotactic Body Radiotherapy in Patients With BCLC Stage C Hepatocellular Carcinoma With Thrombus and/or Extrahepatic Oligometastases (BITS-TO-HCC): Study Protocol of a Prospective, Single- Center, Single-Arm, Phase II Study

Recruiting·SShandong Cancer Hospital and Institute·Phase 2·NCT07062055·54 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Endoscopic Ultrasound Radiofrequency Ablation and Immunotherapy Pembrolizumab for Locally Advanced Unresectable and Metastatic Pancreatic Duct Adenocarcinoma; a Phase II Trial PANcreas CAncer RaDIofrequeNcy AbLation

Recruiting·TThe University of Texas Health Science Center, Houston·Phase 2·NCT06831136·24 enrolled

Metastatic Tumors1 trial

A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for the Comprehensive Treatment of 4-10 Oligometastatic Tumors (SABR-COMET 10)

Active, not recruiting·DDavid Palma·Phase 3·NCT03721341·204 enrolled

HCC - Hepatocellular Carcinoma1 trial

Shuganhuazhuo Formula (Chinese Herbal Medicine) in the Combined Treatment of Advanced Hepatocellular Carcinoma With Damp-Heat and Blood Stasis Syndrome: An Open-Label Randomized Controlled Trial

Not yet recruiting·XXiang-Qian·Phase 2·NCT07691645·120 enrolled

Metastatic Lung Non-Small Cell Carcinoma1 trial

An Interventional Study of PET/CT Changes During Chemoimmunotherapy and Radiation Therapy for Patients With Metastatic NSCLC (PET Bright)

Recruiting·UUniversity of Washington·Preclinical·NCT04151940·80 enrolled

Solid Tumor1 trial

A Phase 1 Study of MOMA-341 as Monotherapy or Combination Therapy in Participants With Advanced or Metastatic Solid Tumors

Recruiting·MMOMA Therapeutics·Phase 1·NCT06974110·132 enrolled

Recurrent Respiratory Papillomatosis1 trial

A Phase 1 Study Of The Safety And Immunogenicity Of Peptide-loaded Autologous Dendritic Cell Vaccination In Recurrent Respiratory Papillomatosis (RRP) Patients

Recruiting·MMayo Clinic·Phase 1·NCT07317154·9 enrolled

Unspecified3 trials

A Benefit Population Atlas of nICT Versus nCT for LAGC

Completed·CCheng Chen··NCT07098104·291 enrolled

SUBLIVAC® Birch PROBE Study

Completed·HHAL Allergy·Phase 2·NCT00932607·74 enrolled

Long-Term Effects of Sublingual Grass Therapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT01335139·106 enrolled

Sources

References

[1]
ClinicalTrials.gov — 108 trial records for Immunotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Immunotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Immunotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bristol-Myers Squibb company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Bristol-Myers Squibb

Immunotherapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q2 2027

Q4 2027

Trials by Indication[1]

Non-Small Cell Lung Cancer12 trials

Immunotherapy10 trials

Lung Cancer5 trials

Esophageal Cancer4 trials

Esophageal Squamous Cell Carcinoma3 trials

Immunochemotherapy3 trials

Melanoma3 trials

Advanced NSCLC2 trials

Chemoradiotherapy2 trials

Neoadjuvant Therapy2 trials

Breast Cancer2 trials

Immune Checkpoint Inhibitors2 trials

Small Cell Lung Cancer2 trials

Allergic Asthma2 trials

Locally Advanced2 trials

Neoadjuvant Chemotherapy2 trials

Neoadjuvant Immunotherapy2 trials

Medication2 trials

Colorectal Cancer2 trials

Camrelizumab1 trial

Gastroesophageal Junction Adenocarcinoma1 trial

Head and Neck Cancers1 trial

Safety and Efficacy1 trial

Organoid1 trial

Uveal Melanoma1 trial

Rectal Cancer1 trial

Adjuvant Chemotherapy1 trial

Effects of Immunotherapy1 trial

Crohn's Disease1 trial

Immune Checkpoint Inhibitor1 trial

NSCLC1 trial

Hematologic Malignancies1 trial

Non-Small Cell Lung Carcinoma1 trial

Bladder Cancer1 trial

Metastatic Melanoma1 trial

Chemotherapy1 trial

Gastroparesis1 trial

Pathological Complete Response1 trial

Head and Neck Squamous Cell Carcinoma1 trial

Prostate Cancer1 trial

Skin Cancer1 trial

ESS1 trial

Hypofractionated Radiotherapy1 trial

Treatment Duration1 trial

Metastatic Colorectal Cancer1 trial

Oligometastases1 trial

Efficacy and Safety1 trial

Rhinitis1 trial

Allergic Rhinitis1 trial

Atopic Dermatitis1 trial

Efficacy1 trial

Asthma1 trial

Breast Carcinoma1 trial

Hepatocellular Carcinoma1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Metastatic Tumors1 trial

HCC - Hepatocellular Carcinoma1 trial

Metastatic Lung Non-Small Cell Carcinoma1 trial

Solid Tumor1 trial

Recurrent Respiratory Papillomatosis1 trial

Unspecified3 trials

References

Drug Info

Quick Facts

Related News